Retinal pigment epithelial cell replacement therapy - Cell Cure Neurosciences

Drug Profile

Retinal pigment epithelial cell replacement therapy - Cell Cure Neurosciences

Alternative Names: OpRegen; OpRegen-Plus; OpRegen® RPE cells

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cell Cure Neurosciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Dry age-related macular degeneration

Most Recent Events

  • 15 Mar 2018 Phase-I/II clinical trials in Dry age-related macular degeneration in USA (Intraocular) before March 2018
  • 17 Jan 2018 BioTime has patent protection for Retinal pigment epithelial cell replacement therapy in USA, Canada and Hong Kong
  • 17 Jan 2018 BioTime has patent protection for Pluripotent cell technology in USA, Japan, Singapore, India and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top